CureVac has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. under which CureVac will collaborate with Crucell Holland B.V. (a Janssen Pharmaceutical member company) on the development of an flu vaccine based on CureVac’s RNActive technology. CureVac’s technology platform with RNActive vaccines has demonstrated effectiveness and safety in several clinical trials.   CureVac will develop optimized RNActive vaccines based on Crucell’s proprie...